Substance P (TFA)

OC(C(F)(F)F)=O.O=C([C@H]1N(CCC1)C([C@@H](N)CCCNC(N)=N)=O)N[C@@H](CCCCN)C(N2[C@@H](CCC2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)CC3=CC=CC=C3)=O)CC4=CC=CC=C4)=O)=O)=O)=O

[1]Grady EF, et al. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell. 1995 May;6 (5) :509-24.|[2]Zhang L, et al. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis. Cell Prolif. 2018 Oct 17:e12527.

Mol Med Rep. 2022 Feb;25 (2) :50.|Authorea. 2023 Aug 14.|Cell Discov. 2023 Jun 30;9 (1) :66.|Cell Prolif. 2019 Jan;52 (1) :e12527.|Chin J Comp Med. May 2018, Vol. 28. No. 5|Eur J Pharmacol. 2023 Sep 15:955:175902.|Eur J Pharmacol. 2025 Sep 24:178189.|FASEB J. 2025 Jul 31;39 (14) :e70817.|Food Sci Nutr. 2025 Sep 1;13 (9) :e70877.|Free Radic Biol Med. 2023 Oct 5;209 (Pt 1) :1-8.|Immunol Lett. 2024 Dec:270:106934.|Int J Biol Sci. 2024 Apr 22;20 (7) :2507-2531.|iScience. 2023 Apr 18;26 (5) :106688.|J Am Soc Mass Spectrom. 2020 Jul 5.|J Headache Pain. 2024 Aug 28;25 (1) :141.|J Immunol Res. 2022 May 12;2022:5582811.|J Invest Dermatol. 2023 May;143 (5) :812-821.e3.|J Invest Dermatol. 2025 Nov 4:S0022-202X (25) 03517-1.|Mol Biol Rep. 2022 Mar;49 (3) :2227-2236.|Prog Neurobiol. 2021 Jul:202:102041.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2021 Jul.|Research Square Preprint. 2021 Sep.|SSRN. 2025 Feb 24.